The intended audience for this activity is comprehensive ophthalmologists, retinal specialists and other health care professionals involved in the management of patients with retinal diseases.
Upon successful completion of this activity, participants should be better able to:
- Review the burden associated with current therapies used for the treatment of neovascular retinal diseases.
- Assess the long-term effects of anti-VEGF therapy on vision, the potential for complications, and patient outcomes.
- Summarize the evidence demonstrated in major clinical trials regarding treatment protocols and their application to real-world practice in the treatment of neovascular retinal diseases.
- Examine the role of persistent retinal fluid in determining response to treatment in neovascular retinal diseases.
- Evaluate new and emerging modalities that may reduce the burden of anti-VEGF therapy in neovascular retinal diseases.
- Describe emerging delivery systems that allow for extended intervals between treatment for neovascular retinal diseases.
For more session-specific CME information, please visit the registration sites.